Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is
inhibited by a new series of pyridinyl-imidazole compounds. Using radiolabelled and radio-…

The site of action of a series of pyridinyl imidazole compounds that are selective inhibitors of
p38 mitogen-activated protein kinase in vitro and block proinflammatory cytokine production …

SB 203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)imidazole], a
selective cytokine suppressive binding protein/p38 kinase inhibitor, was evaluated in several …

Since the discovery of p38 MAP kinase in 1994, our understanding of its biology has progressed
dramatically. The key advances include (1) identification of p38 MAP kinase homologs …

Background: The mitogen-activated protein (MAP) kinases are important signaling molecules
that participate in diverse cellular events and are potential targets for intervention in …

The regulatory approval of ipilimumab (Yervoy) in 2011 ushered in a new era of cancer
immunotherapies with durable clinical effects. Most of these breakthrough medicines are …

The effects of a second generation p38 mitogen-activated protein kinase (MAPK) inhibitor,
SB 239063 [trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)…

The pyridinylimidazole compounds, exemplified by SB 203580, originally were prepared as
inflammatory cytokine synthesis inhibitors. Subsequently, the compounds were found to be …

p38 MAPK is a Ser/Thr protein kinase activated by various inflammatory cytokines and a
variety of stress stimuli. It is involved in many physiological processes, including the production …

While a great deal has been discovered concerning the potential physiological and pathological
role of prostanoids, much is left to be determined. The widespread distribution of both …